This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (39)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

The Effect of Adding Prostaglandin F2-Isopropylester to Timolol in Patients With Open Angle Glaucoma

Jörgen Villumsen, MD; Albert Alm, MD

Arch Ophthalmol. 1990;108(8):1102-1105.

Abstract
• Prostaglandin F₂-isoprophylester (PGF₂-IE) (0.5 µg) or placebo was added twice daily for 1 week to one eye in each of 30 patients with open angle glaucoma not adequately controlled with timolol treatment. Compared with placebo, PGF₂-IE reduced the intraocular pressure of these timolol-treated eyes significantly. The absolute difference in mean change between PGF₂-IE and placebo groups was 4.5 mm Hg with a 95% confidence interval of 3.1 to 6.6 mm Hg, corresponding to a mean reduction of initial intraocular pressure of 17.4% in eyes treated with PGF₂-IE. Conjunctival or episcleral hyperemia was seen in all eyes treated with PGF₂-IE for up to 4 hours but not in eyes treated with timolol and placebo, and aqueous flare was not observed in any eye. Thirteen of 15 patients treated with PGF₂-IE, compared with only 3 of 15 who received placebo, reported mild to moderate subjective discomfort in the treated eye in the form of a foreign-body sensation that lasted for up to 2 hours. These results demonstrate that PGF₂-IE, in a dose that has previously been shown to reduce intraocular pressure in normotensive volunteers or in patients with glaucoma who are taking no other medications, also significantly reduces the intraocular pressure of patients with glaucoma whose pressures are not adequately controlled on a twicedaily regimen of timolol.

Author Affiliations
From the Department of Ophthalmology, University Hospital, Umeå, Sweden.

Footnotes
Accepted for publication March 15, 1990.

Reprint requests to Department of Ophthalmology, University Hospital, S-901 85 Umeå, Sweden (Dr Alm).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

From PGF2{{alpha}}-Isopropyl Ester to Latanoprost: A Review of the Development of Xalatan The Proctor Lecture
Stjernschantz
IOVS 2001;42:1134-1145.
FULL TEXT  

Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with beta adrenergic antagonists
Nordmann et al.
Br J Ophthalmol 2000;84:181-185.
ABSTRACT | FULL TEXT  

Medical Management of Glaucoma
Alward
NEJM 1998;339:1298-1307.
FULL TEXT  

The Effects on Aqueous Dynamics of PhXA41, a New Prostaglandin F2{alpha} Analogue, After Topical Application in Normal and Ocular Hypertensive Human Eyes
Ziai et al.
Arch Ophthalmol 1993;111:1351-1358.
ABSTRACT  

Interaction of PhXA41, a New Prostaglandin Analogue, With Pilocarpine: A Study on Patients With Elevated Intraocular Pressure
Fristrom and Nilsson
Arch Ophthalmol 1993;111:662-665.
ABSTRACT  

Randomized Clinical Trials on Medical Treatment of Glaucoma: Are They Appropriate to Guide Clinical Practice?
Rossetti et al.
Arch Ophthalmol 1993;111:96-103.
ABSTRACT  

Intraocular Pressure Reduction With PhXA34, a New Prostaglandin Analogue, in Patients With Ocular Hypertension
Camras et al.
Arch Ophthalmol 1992;110:1733-1738.
ABSTRACT  

PhXA34, a New Potent Ocular Hypotensive Drug: A Study on Dose-Response Relationship and on Aqueous Humor Dynamics in Healthy Volunteers
Alm and Villumsen
Arch Ophthalmol 1991;109:1564-1568.
ABSTRACT